Compare PBHC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | ACET |
|---|---|---|
| Founded | 1859 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 71.3M |
| IPO Year | N/A | N/A |
| Metric | PBHC | ACET |
|---|---|---|
| Price | $14.34 | $8.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $96.67 |
| AVG Volume (30 Days) | 3.1K | ★ 199.8K |
| Earning Date | 01-30-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $44,154,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 24.40 | N/A |
| 52 Week Low | $13.35 | $7.15 |
| 52 Week High | $17.50 | $17.44 |
| Indicator | PBHC | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 75.57 |
| Support Level | $13.96 | $7.70 |
| Resistance Level | $14.38 | $8.56 |
| Average True Range (ATR) | 0.30 | 0.53 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 86.08 | 23.78 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.